{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:00:37Z","timestamp":1781632837643,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Natural Science Foundation of Fujian Province","award":["2023 J01715"],"award-info":[{"award-number":["2023 J01715"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Essential thrombocythemia (ET) is a kind of myeloproliferative neoplasms. Thrombosis is one of the common symptoms, however, the incidence of thrombosis in ET with\n                    <jats:italic>JAK2<\/jats:italic>\n                    ,\n                    <jats:italic>CALR<\/jats:italic>\n                    ,\n                    <jats:italic>MPL<\/jats:italic>\n                    gene mutations varies greatly, and the underlying mechanism is unclear. The clinical data of 155 consecutive patients with ET were analyzed retrospectively. The plasminogen activator inhibitor-1 (PAI-1) 4G\/5G polymorphism and plasma levels were measured by sequencing reaction universal kit and enzyme linked immunosorbent assay (ELISA), respectively. The mutational status in ET was detected by polymerase chain reaction (PCR). Thrombotic events were detected by Color Doppler Ultrasound, Computer Tomography (CT), Magnetic Resonance Imaging (MRI), angiography and D-dimer. Among 155 patients with ET, 21.3% (33\/155) had thrombotic events, including 54.5% (18\/33) of ischemic stroke, 36.4% (12\/33) of ischemic heart disease and 9.1% (3\/33) of venous thrombosis. Compared to the healthy control population, there was no significant difference between the occurrence of thrombotic events and the patient\u2019s age, gender, and blood cell counts, except for platelet counts. The incidence of thrombotic events in\n                    <jats:italic>JAK2 V617F<\/jats:italic>\n                    mutation positive ET patients was significantly higher than that in\n                    <jats:italic>CALR<\/jats:italic>\n                    mutation positive and\n                    <jats:italic>JAK2 V617F<\/jats:italic>\n                    mutation negative ET patients (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05). The gene 4G4G polymorphism and plasma levels of PAI-1 in\n                    <jats:italic>JAK2 V617F<\/jats:italic>\n                    mutated ET patients were significantly higher than that in\n                    <jats:italic>CALR<\/jats:italic>\n                    mutated ET patients, respectively (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05). In patients with\n                    <jats:italic>JAK2 V617F<\/jats:italic>\n                    mutation positive ET, the incidence of thrombosis in 4G4G gene group and plasma levels of PAI-1 group were significantly higher than that in non 4G4G group, respectively (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05). The 4G4G gene polymorphism and high plasma levels of PAI-1 have potential value in predicting the risk factors for thrombosis in\n                    <jats:italic>JAK2 V617F<\/jats:italic>\n                    mutation positive ET compare to\n                    <jats:italic>CALR<\/jats:italic>\n                    mutation positive subjects.\n                  <\/jats:p>","DOI":"10.1186\/s12959-026-00828-x","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T11:13:24Z","timestamp":1768648404000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["4G\/5G polymorphism and plasma levels of plasminogen activator inhibitor-1 in essential thrombocythemia patients with driver mutational status"],"prefix":"10.1186","volume":"24","author":[{"given":"Xueya","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xizhe","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,17]]},"reference":[{"issue":"9","key":"828_CR1","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1038\/leu.2017.150","volume":"31","author":"L Falchi","year":"2017","unstructured":"Falchi L, Kantarjian HM, Verstovsek S. Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era. Leukemia. 2017;31(9):1845\u201354.","journal-title":"Leukemia"},{"issue":"20","key":"828_CR2","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"key":"828_CR3","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1056\/NEJMra1406186","volume":"376","author":"JL Spivak","year":"2017","unstructured":"Spivak JL. Myeloproliferative neoplasms. N Engl J Med. 2017;376:2168\u201381.","journal-title":"N Engl J Med"},{"key":"828_CR4","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/s41408-024-01169-6","volume":"14","author":"T Barbui","year":"2024","unstructured":"Barbui T, Ghirardi A, Carobbio A, et al. Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors. Blood Cancer J. 2024;14:188.","journal-title":"Blood Cancer J"},{"key":"828_CR5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/ejh.13373","volume":"104","author":"E Ahlstrand","year":"2020","unstructured":"Ahlstrand E, Samuelsson J, Lindgren M, et al. Highly reduced survival in essential thrombocythemia and polycythemia Vera patients with vascular complications during follow-up. Eur J Haematol. 2020;104:271\u20138.","journal-title":"Eur J Haematol"},{"issue":"16","key":"828_CR6","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507\u201313.","journal-title":"Blood"},{"key":"828_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","volume":"1","author":"A Tefferi","year":"2015","unstructured":"Tefferi A, Pardanani A. Myeloproliferative neoplasms: a contemporary review. JAMA Oncol. 2015;1:97\u2013105.","journal-title":"JAMA Oncol"},{"key":"828_CR8","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","volume":"120","author":"T Barbui","year":"2012","unstructured":"Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an international prognostic score of thrombosis in world health organization\u2013essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120:5128\u201333.","journal-title":"Blood"},{"issue":"4","key":"828_CR9","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/ajh.24293","volume":"91","author":"M Haider","year":"2016","unstructured":"Haider M, Gangat N, Lasho T, et al. Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo clinic patients. Am J Hematol. 2016;91(4):390\u20134.","journal-title":"Am J Hematol"},{"issue":"8","key":"828_CR10","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/eci.12647","volume":"46","author":"I Bertozzi","year":"2016","unstructured":"Bertozzi I, Peroni E, Coltro G, et al. Thrombotic risk correlates with mutational status in true essential thrombocythemia. Eur J Clin Invest. 2016;46(8):683\u20139.","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"828_CR11","doi-asserted-by":"publisher","first-page":"E26","DOI":"10.1002\/ajh.27148","volume":"99","author":"N Neupane","year":"2024","unstructured":"Neupane N, Low SK, Kharel H, et al. Comparative thrombotic risk associated with CALR1, CALR2, and JAK2 V617F mutations in\u2002essential\u2002thrombocythemia. Am J Hematol. 2024;99(1):E26. - E28.","journal-title":"Am J Hematol"},{"issue":"21","key":"828_CR12","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1161\/01.CIR.98.21.2241","volume":"98","author":"AM Thogersen","year":"1998","unstructured":"Thogersen AM, Jansson JH, Boman K, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation. 1998;98(21):2241\u20137.","journal-title":"Circulation"},{"key":"828_CR13","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1161\/01.CIR.0000066908.82782.3A","volume":"107","author":"F Andreas","year":"2003","unstructured":"Andreas F, Ralph D, Rich SS, et al. Promoter (4G\/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the insulin resistance atherosclerosis study. Circulation. 2003;107:2422.","journal-title":"Circulation"},{"issue":"1","key":"828_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12959-021-00294-7","volume":"19","author":"X Zhang","year":"2021","unstructured":"Zhang X, Guo X. Risk factors of thrombosis in Chinese subjects with acute promyelocytic leukemia. Thromb J. 2021;19(1):42.","journal-title":"Thromb J"},{"key":"828_CR15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/ajh.10192","volume":"71","author":"G Balta","year":"2010","unstructured":"Balta G, Altay C, Gurgey A. PAI-1 gene 4G\/5G genotype: a risk factor for thrombosis in vessels of internal organs. Am J Hematol. 2010;71:89\u201393.","journal-title":"Am J Hematol"},{"key":"828_CR16","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.cardiores.2004.11.013","volume":"66","author":"Y Koji","year":"2005","unstructured":"Koji Y, Kyosuke T, Tetsuhito K, et al. Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly. Cardiovasc Res. 2005;66:276\u201385.","journal-title":"Cardiovasc Res"},{"issue":"24","key":"828_CR17","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1056\/NEJM200006153422406","volume":"342","author":"HP Kohler","year":"2000","unstructured":"Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med. 2000;342(24):1792\u2013801.","journal-title":"N Engl J Med"},{"key":"828_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.thromres.2016.02.002","volume":"140","author":"GH Tofler","year":"2016","unstructured":"Tofler GH, Massaro J, O\u2019Donnell CJ, et al. Plasminogen activator inhibitor and the risk of cardiovascular disease: the Framingham heart study. Thromb Res. 2016;140:30\u20135.","journal-title":"Thromb Res"},{"issue":"8","key":"828_CR19","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1177\/1076029617705728","volume":"23","author":"MS Akhter","year":"2017","unstructured":"Akhter MS, Biswas A, Abdullah SM, et al. The role of PAI-1 4G\/5G promoter polymorphism and its levels in the development of ischemic stroke in young Indian population. Clin Appl Thromb Hemost. 2017;23(8):1071\u20136.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"1","key":"828_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13018-018-0716-2","volume":"13","author":"J Tang","year":"2018","unstructured":"Tang J, Zhu W, Mei X, et al. Plasminogen activator inhibitor-1: a risk factor for deep vein thrombosis after total hip arthroplasty. J Orthop Surg Res. 2018;13(1):8.","journal-title":"J Orthop Surg Res"},{"issue":"1","key":"828_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12959-022-00430-x","volume":"20","author":"Z Wang","year":"2022","unstructured":"Wang Z, Kong L, Luo G, et al. Clinical impact of the\u2002PAI-1 4G\/5G polymorphism in Chinese patients with venous thromboembolism. Thromb J. 2022;20(1):68.","journal-title":"Thromb J"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-026-00828-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-026-00828-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-026-00828-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:47:48Z","timestamp":1781632068000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12959-026-00828-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,17]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["828"],"URL":"https:\/\/doi.org\/10.1186\/s12959-026-00828-x","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,17]]},"assertion":[{"value":"3 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of The Second Affiliated Hospital of Fujian Medical University, approval number [2025087].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Tables\u00a0\n                      \n                      ,\n                      \n                      ,\n                      \n                      ,\n                      \n                      ,\n                      \n                      and\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}